Dare Bioscience News

News

Ticker

DARE

ISIN

US23666P2002

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Dare Bioscience Eulerpool News

Dare Bioscience Stock News

Dare Bioscience is being monitored by journalists and investors worldwide. We gather the latest Dare Bioscience news here.

March 17·
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 16·
Benzinga
Daré Bioscience Gets ~$2M Funding From National Institutes Of Health's Division For Its Intravaginal Ring DARE-PTB1 For Prevention Of Preterm Birth
March 2·
Yahoo
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
February 23·
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 23·
Yahoo
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
February 23·
Benzinga
Daré Bioscience Announces FDA Clears Its Investigational New Drug Application For DARE-HPV To Initiate Planned Phase 2 Clinical Study For Papillomavirus Infection Treatment
February 11·
Yahoo
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
January 20·
Yahoo
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth
November 24·
Yahoo
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
November 24·
Benzinga
Daré Bioscience Receives About $3.6M Payment Under Existing Grant Agreement With Gates Foundation
November 22·
SeekingAlpha
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript
November 13·
Benzinga
Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate
September 4·
Benzinga
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
August 15·
Yahoo
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ...
August 14·
Yahoo
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14·
Benzinga
Earnings Scheduled For August 14, 2025
August 13·
Benzinga
A Preview Of Dare Bioscience's Earnings
August 12·
Yahoo
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
August 6·
Yahoo
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
July 29·
Benzinga
Daré Bioscience Launch Phase One Of Patient-Focused Campaign With Rosy Wellness To Support DARE To PLAY Sildenafil Cream

Dare Bioscience Stock Press Releases

Dare Bioscience regularly publishes news on the company's website that are relevant for investors.

November 15•
Dare Bioscience
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
November 14•
Dare Bioscience
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
November 10•
Dare Bioscience
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
November 8•
Dare Bioscience
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
November 3•
Dare Bioscience
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
November 1•
Dare Bioscience
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
October 17•
Dare Bioscience
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
October 10•
Dare Bioscience
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
September 15•
Dare Bioscience
Daré Bioscience to Participate in Two Upcoming Conferences
September 6•
Dare Bioscience
Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
August 29•
Dare Bioscience
Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
August 24•
Dare Bioscience
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
August 9•
Dare Bioscience
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
August 2•
Dare Bioscience
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
July 7•
Dare Bioscience
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
June 30•
Dare Bioscience
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
June 24•
Dare Bioscience
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
June 6•
Dare Bioscience
Daré Bioscience to Participate in the 2022 BIO International Convention
May 16•
Dare Bioscience
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
May 12•
Dare Bioscience
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
May 11•
Dare Bioscience
Daré Bioscience Announces NIH Grant Award
May 5•
Dare Bioscience
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
April 14•
Dare Bioscience
Daré Bioscience to Participate in Upcoming Conference
April 12•
Dare Bioscience
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
March 31•
Dare Bioscience
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
March 31•
Dare Bioscience
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
March 24•
Dare Bioscience
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
March 22•
Dare Bioscience
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
March 2•
Dare Bioscience
Daré Bioscience to Participate in Upcoming Conferences
February 7•
Dare Bioscience
Daré Bioscience to Participate in Upcoming Conferences

Dare Bioscience News 2026

This page contains all current news, analysis and press releases for Dare Bioscience stock (DARE, ISIN: US23666P2002). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Dare Bioscience.